Celcuity Inc. (CELC)
NASDAQ · Services · Services-medical laboratories
CELC price, last 12 months
Key stats
- Previous close
- $79.37
- Open
- $80.00
- Day range
- $78.02 – $80.28
- 52-week range
- $44.42 – $151.02
- Volume
- 657.2K
- Avg volume (20 days)
- 875.1K
- Market cap
- $3.9B
Performance
Technicals and fundamentals
About Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
- Sector
- Services
- Industry
- Services-medical laboratories
- Listed on
- NASDAQ
- Market cap
- $3.9B